Cel Sci Corp Stock Investor Sentiment

CVM Stock  USD 0.69  0.05  6.76%   
About 61% of CEL SCI's investor base is looking to short. The analysis of the overall investor sentiment regarding CEL SCI Corp suggests that many traders are alarmed. CEL SCI's investing sentiment overview a quick insight into current market opportunities from investing in CEL SCI Corp. Many technical investors use CEL SCI Corp stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
  
few days ago at finance.yahoo.com         
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration He...
Yahoo News
six days ago at finance.yahoo.com         
CVM CRO Selected for Registrational Trial
Yahoo News
over two weeks ago at www.macroaxis.com         
Acquisition by Daniel Zimmerman of 80000 shares of CEL SCI at 3.35 subject to Rule 16b-3
Macroaxis News
over a month ago at news.google.com         
CVM stock touches 52-week low at 0.68 amid sharp annual decline - Investing.com
Google News at Macroaxis
over a month ago at finance.yahoo.com         
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Mar...
Yahoo News
over a month ago at seekingalpha.com         
CEL-SCI files to sell 1M shares of common stock for holders
seekingalpha News
over a month ago at finance.yahoo.com         
FDAs Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of...
Yahoo News
over a month ago at news.google.com         
CVM stock touches 52-week low at 0.93 amid market challenges - Investing.com
Google News at Macroaxis
over two months ago at www.macroaxis.com         
Disposition of 64000 shares by Gobbo Mario of CEL SCI at 1.5 subject to Rule 16b-3
Macroaxis News
over two months ago at finance.yahoo.com         
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine i...
Yahoo News
over two months ago at prnewswire.com         
Nucleus Security Named a Leader in the GigaOm Radar Report for Continuous Vulnerability Management
prnewswire News
over three months ago at finance.yahoo.com         
CEL-SCIs Multikine Increased 5-Year Survival Rate to 82.6 percent in Locally Advanced Resectable Hea...
Yahoo News
over three months ago at thelincolnianonline.com         
Black Diamond Financial LLC Grows Position in CEL-SCI Co.
news
over three months ago at www.macroaxis.com         
Acquisition by Peter Young of 3000 shares of CEL SCI at 12.657 subject to Rule 16b-3
Macroaxis News
over three months ago at finance.yahoo.com         
CEL-SCI to Present New Data for Multikine Head Neck Cancer Immunotherapy at the European Society for...
Yahoo News
Far too much social signal, news, headlines, and media speculation about CEL SCI that are available to investors today. That information is available publicly through CEL media outlets and privately through word of mouth or via CEL internal channels. However, regardless of the origin, that massive amount of CEL data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CEL SCI news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CEL SCI relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CEL SCI's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CEL SCI alpha.

CEL SCI Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine in Head and Neck Cancer
10/01/2024
2
Disposition of 64000 shares by Gobbo Mario of CEL SCI at 1.5 subject to Rule 16b-3
10/14/2024
3
FDAs Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCIs Multikine to Address Major Treatment Gap for PD-L1...
10/22/2024
4
CVM stock touches 52-week low at 0.68 amid sharp annual decline - Investing.com
11/13/2024
5
Acquisition by Daniel Zimmerman of 80000 shares of CEL SCI at 3.35 subject to Rule 16b-3
11/29/2024
6
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
12/12/2024
When determining whether CEL SCI Corp is a strong investment it is important to analyze CEL SCI's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact CEL SCI's future performance. For an informed investment choice regarding CEL Stock, refer to the following important reports:
Check out CEL SCI Hype Analysis, CEL SCI Correlation and CEL SCI Performance.
You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CEL SCI. If investors know CEL will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CEL SCI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.52)
Revenue Per Share
0.001
Quarterly Revenue Growth
(0.63)
Return On Assets
(0.61)
Return On Equity
(2.50)
The market value of CEL SCI Corp is measured differently than its book value, which is the value of CEL that is recorded on the company's balance sheet. Investors also form their own opinion of CEL SCI's value that differs from its market value or its book value, called intrinsic value, which is CEL SCI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CEL SCI's market value can be influenced by many factors that don't directly affect CEL SCI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CEL SCI's value and its price as these two are different measures arrived at by different means. Investors typically determine if CEL SCI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CEL SCI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.